Fluciclovine
Genital Diseases, Male
VA Greater Los Angeles Healthcare SystemradiopharmaceuticalPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Genital Diseases, Male cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
STI571 Novartis Pharmaceuticals | Phase 2 | B |
PSMA-HBED-CC ALF-18 Alessandro D'Agnolo | Phase 2 | B |
Ixabepilone Cedars-Sinai Medical Center | Phase 2 | CCC |
Darolutamide Celcuity Inc | Phase 1/2 | CCC |
Epi-506 ESSA Pharmaceuticals | Phase 1/2 | CC |
View all 9 →
Same molecule, other indications
Fluciclovine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →